The Lm-GP61 vaccine developed using the CD4+ T cell epitopes can impede tumor progression by inducing TH1 and CTL responses, synergizing PD-L1 blockade to mediate tumor suppression (83). This evidence concerns the gene CD274 and neoplasm.